[Treatment of Raynaud's phenomenon].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use; D006801:Humans; D007650:Ketanserin / Q000627:therapeutic use*; D011453:Prostaglandins / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers; D011453:Prostaglandins; D007650:Ketanserin; D002216:Captopril
Traitement du phénomène de Raynaud.